Applied Filters
New recipes for Tomatoes and Broccoli
Controversial patents covering a fruit and a vegetable are awaiting their fate at the Enlarged Board of Appeal. LSIPR examines the likelihood of their succeeding.
After Alice: the two-step rule
Existing portfolios should be carefully reviewed and care must be taken in drafting new patent applications to withstand section 101 scrutiny in the US, as Judith Kim, director, and Scott Schaller, of counsel, at Sterne Kessler Goldstein & Fox, describe.
PlasmaTech: two strings to its bow
At first glance, it might seem odd for a company to both divide blood plasma and fight the side-effects of cancer treatment. But not for PlasmaTech Biopharmaceuticals, which tells LSIPR about how the company does it and also protects its IP.
Pursuing agribusiness infringement actions in Brazil
Protecting rights related to desirable plant species is a delicate process, says Gabriel Di Blasi.
Patenting Parthenotes
Earlier this year, the Advocate General of the CJEU opined that stem cells from parthenotes are patentable. Franz-Josef Zimmer and Markus Grammel examine the reasoning behind his opinion.
A changing landscape: approving biosimilar products in Mexico
Who has legal interest in the grant of sanitary registrations for follow-on biologics? José Trigueros examines a recent case in Mexico that could have far-reaching ramifications.
Ebola IP rights in focus
The current outbreak of Ebola has devastated communities in West Africa. It has also thrown a light on the complex web of IP rights surrounding the possible treatments for this serious and usually fatal virus, as LSIPR discovered.
HGS: where are we now with SPCs?
Should it be possible for a drug maker to stop the owner of a patented ingredient from obtaining an SPC? Ashley Roughton examines the CJEU’s opinion on Eli Lilly v HGS.
Challenges to the patenting of “essentially biological processes” in India
A recent decision from the IPAB on the patent eligibility of biological processes could change the biotech playing field in India, say Swarup Kumar and Shivaarti Bajaj.
An alliance for science
The Bay Area of California has one of the greatest concentrations of life sciences companies in the world, but its biotech community is being threatened by the seemingly unstoppable rise of large technology businesses. LSIPR spoke to Christopher Stewart, chair, and Robert Eyler, vice chair, of the new North Bay Life Science Alliance to find out how it plans to strengthen the network in the area.
